{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T04:57:57Z","timestamp":1788238677329,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T00:00:00Z","timestamp":1530576000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1093\/omcr\/omy038","type":"journal-article","created":{"date-parts":[[2018,7,3]],"date-time":"2018-07-03T08:49:45Z","timestamp":1530607785000},"source":"Crossref","is-referenced-by-count":4,"title":["Successful eradication of leptomeningeal plasma cell disease"],"prefix":"10.1093","volume":"2018","author":[{"given":"\u00d8yvind","family":"Bruserud","sequence":"first","affiliation":[{"name":"Section for Endocrinology, Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent-Are","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Microbiology, F\u00f8rde Hospital, F\u00f8rde, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Vetti","sequence":"additional","affiliation":[{"name":"Department of Radiology, Haukeland University Hospital, Bergen, Norway"},{"name":"Section for Radiology, Department of Clinical Medicine, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silje","family":"Johansen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kon","family":"Reikvam","sequence":"additional","affiliation":[{"name":"Department of Medicine, Haukeland University Hospital, Bergen, Norway"},{"name":"Section for Haematology, Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,7,3]]},"reference":[{"key":"key\n\t\t\t\t2019020511403079500_omy038C1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ejh.12533","article-title":"Plasma cell leukemia: from biology to treatment","volume":"95","author":"Jelinek","year":"2015","journal-title":"Eur J Haematol"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/archneur.61.9.1423","article-title":"Multiple myeloma invasion of the central nervous system","volume":"61","author":"Schluterman","year":"2004","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C3","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/leu.2015.80","article-title":"Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma","volume":"29","author":"Mai","year":"2015","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C4","first-page":"Cd010816","article-title":"Bortezomib for the treatment of multiple myeloma","volume":"4","author":"Scott","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2214\/AJR.13.10856","article-title":"MRI features of extramedullary myeloma","volume":"202","author":"Tirumani","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C6","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clinimag.2014.11.017","article-title":"Imaging of extraosseous intracranial and intraspinal multiple myeloma, including central nervous system involvement","volume":"39","author":"Shpilberg","year":"2015","journal-title":"Clin Imaging"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.crad.2015.03.014","article-title":"Intracranial involvement by multiple myeloma","volume":"70","author":"Lasocki","year":"2015","journal-title":"Clin Radiol"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C8","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.12414","article-title":"Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents","volume":"162","author":"Chen","year":"2013","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C9","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C10","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/cncr.26447","article-title":"Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients","volume":"118","author":"Gozzetti","year":"2012","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C11","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/cncr.23330","article-title":"Myelomatous meningitis","volume":"112","author":"Chamberlain","year":"2008","journal-title":"Cancer"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1871524914999140818111514","article-title":"Novel agents in CNS myeloma treatment","volume":"14","author":"Gozzetti","year":"2014","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C13","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.4081\/hr.2017.6986","article-title":"Successful intrathecal chemotherapy combined with radiotherapy followed by pomalidomide and low-dose dexamethasone maintenance therapy for a primary plasma cell leukemia patient","volume":"9","author":"Yamashita","year":"2017","journal-title":"Hematol Rep"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.3109\/10428194.2012.718343","article-title":"Effective treatment of pomalidomide in central nervous system myelomatosis","volume":"54","author":"Mussetti","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C15","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C16","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.jpba.2013.08.036","article-title":"Sensitive liquid chromatography\/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue","volume":"88","author":"Jiang","year":"2014","journal-title":"J Pharm Biomed Anal"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1586\/ehm.12.62","article-title":"Immunomodulatory drugs in multiple myeloma","volume":"6","author":"Andhavarapu","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/14656566.2018.1441287","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"19","author":"Scalzulli","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/bjh.14987","article-title":"A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results","volume":"180","author":"Spencer","year":"2018","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bjh.14498","article-title":"Marizomib for central nervous system-multiple myeloma","volume":"177","author":"Badros","year":"2017","journal-title":"Br J Haematol"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C21","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.1451","article-title":"Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab","author":"Elhassadi","year":"2018","journal-title":"Clin Case Rep"},{"key":"key\n\t\t\t\t2019020511403079500_omy038C22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2217\/imt-2017-0136","article-title":"Emerging immune targets for the treatment of multiple myeloma","volume":"10","author":"Sohail","year":"2018","journal-title":"Immunotherapy"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/omcr\/article-pdf\/2018\/7\/omy038\/27710653\/omy038.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T17:19:58Z","timestamp":1549387198000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omy038\/5048230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,1]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,3]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omy038","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7]]},"published":{"date-parts":[[2018,7,1]]}}}